8TE.F CANNABIS POLAND AB ZY-10

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
0.0210 EUR
Close of Nov 9, 2026
0.0179 0.0500
Market cap
EUR 1.56M
P/E
-
P/B
4.66x
ROE
-180.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 8TE.F undervalued?

Graham number

The Graham number of CANNABIS POLAND AB ZY-10 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CANNABIS POLAND AB ZY-10 fundamental analysis

No fundamental analysis for CANNABIS POLAND AB ZY-10 yet.

CANNABIS POLAND AB ZY-10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CANNABIS POLAND AB ZY-10

Cannabis Poland S.A. operates in the medical cannabis industry in Poland. It distributes and sells cannabidiol (CBD) oils and herbs, inhalers, and vaporizers, as well as dietary supplements and cosmetics for humans and animals. The company sells its products through HempWish.pl and Vapem.eu online stores. It also engages in the research and development of CBD-based drugs based on scientific council, as well as in the operation of MMedu.eu, an educational platform that provid…

Full company profile